Elanco
Overview
Elanco is a global animal health company that develops, manufactures, and markets products and services to prevent and treat diseases in farm animals and pets. The company was formerly a subsidiary of Eli Lilly and Company before becoming fully independent in 2019. While its primary role is an operating company, Elanco also engages in strategic investments, such as co-founding BiomEdit by contributing intellectual property and assets in exchange for equity.
Portfolio Companies
3
Website
elanco.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Athian | Nov 2025 | Series A | Co-investor |
| Reactive Biosciences Inc. | Mar 2017 | Series A | Co-investor |
| Resilient Biotics | Jan 2021 | Series A | Co-investor |
Key People
Sridharan Govind
Director, Vaccine Manufacturing
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Elanco based?
Elanco is headquartered in Greenfield, Indiana, United States.
When was Elanco founded?
Founding year information for Elanco is not publicly available.
How many portfolio companies does Elanco have?
Elanco has 3 portfolio companies in Caplight's dataset.
What are some companies in Elanco's portfolio?
Portfolio companies visible on Caplight include Athian, Reactive Biosciences Inc., Resilient Biotics.
What was Elanco's most recent investment shown here?
Elanco's most recent investment in this portfolio sample was in Athian in 2025.
What sectors does Elanco focus on?
Elanco focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Energy & Sustainability, Enterprise Software, Frontier & Industrial Tech.
What company stages does Elanco focus on?
Elanco typically invests at the Early stage.